Skip to content

Cardiac Manifestation and Inherited Metabolic Diseases

Cardiac Manifestations in Adult Patients With Inherited Metabolic Disease: a Case Series

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04999566
Enrollment
30
Registered
2021-08-11
Start date
2021-05-01
Completion date
2024-09-02
Last updated
2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolism, Inborn Errors

Keywords

Cardiac involvement, Inborn errors of metabolism

Brief summary

The aim of this study is to report and describe cardiac manifestations associated with IMD in a cohort of patients followed in a reference center for rare diseases (Lausanne University Hospital, CHUV) from 2017-2020.

Detailed description

Inherited metabolic diseases (IMD) are genetic disorders resulting from an enzyme defect and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate metabolism or impaired organelle function. As IMDs can affect the primary sources of energy (glycogen, fatty acids), they can lead to cardiac dysfunction. Although most of IMDs are multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main clinical feature and source of major complications which will determine the prognosis, like heart failure, ventricular arrythmias or even sudden death. Information regarding cardiac manifestations in adult IMDs is currently scarce and little is known about their clinical and radiological characteristics. A database was created in 2017 including all patients with IMD followed at the Adult Metabolic Clinic in the CHUV. This database was part of a protocol submitted and approved by the Ethics committee (# 2017-02328). The results of this first analysis were published in the Journal of Orphan Rare Diseases. Investigators will use this database to identify all the patients who had cardiac examination. Only patients from the Lausanne University Hospital followed jointly with the Division of Cardiology will be included in the analysis. Electronic and paper patient charts from the Division of Genetic Medicine and Division of Cardiology (Lausanne University Hospital) will be reviewed for type of IMD and cardiac investigations (cardiac ultrasound, multiple resonance Imaging, electrocardiogram). All variables will be entered in an excel database.

Interventions

None listed

Sponsors

University of Lausanne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All IMD adult patients followed at the adult metabolic clinic at the Lausanne University Hospital from 2017 to 2020 with cardiac investigations

Exclusion criteria

* Age \< 16 years. Any document attesting a refusal to participate will exclude the data entry of the concerned patient

Design outcomes

Primary

MeasureTime frameDescription
Additional cardiac investigations3 yearsECG-QT interval
Right ventricular ejection fraction (%)3 yearsCardiac ultrasound and multiple resonance imaging description of right ventricular ejection fraction
aortic root diameter (mm)3 yearsCardiac ultrasound and multiple resonance imaging description of aortic root diameter
Specific diagnosis of Inborn Errors of Metabolism listed by their frequencyDay 1Clinical outcome
Age at diagnosis (years/months)Day 1Clinical outcome
Current age (years/months)through study completion, an average of 1 yearClinical outcome
Weight (kg)through study completion, an average of 1 yearClinical outcome
Height (cm)through study completion, an average of 1 yearClinical outcome
BMI (kg/m^2)through study completion, an average of 1 yearClinical outcome. Weight and height will be combined to report BMI
Cardiac involvement3 yearsType of complications (restrictive cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrythmia, heart failure, valvlulopathy, cardiomegaly, thrombosis)
Left ventricular mass (g/m^2)3 yearsCardiac ultrasound and multiple resonance imaging description of left ventricular mass
Left ventricular volume (cc/m^2)3 yearsCardiac ultrasound and multiple resonance imaging description of left ventricular volume
Right ventricular volume (cc/m^2)3 yearsCardiac ultrasound and multiple resonance imaging description of right ventricular volume
Left ventricular diameter (mm)3 yearsCardiac ultrasound and multiple resonance imaging description of left ventricular diameter
Left ventricular ejection fraction (%)3 yearsCardiac ultrasound and multiple resonance imaging description of left ventricular ejection fraction

Secondary

MeasureTime frameDescription
Gender (Male/Female)Day 1Demography outcome
Specific treatment for inherited metabolic diseases3 yearsTreatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, vitamin cofactors

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026